Literature DB >> 20686240

Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.

Tomoyoshi Ishikawa1, Takahiko Ito, Ryosuke Endo, Keiko Nakagawa, Eiji Sawa, Kaori Wakamatsu.   

Abstract

Monoclonal antibodies are widely used for the treatment of various diseases, and because therapeutic monoclonal antibodies are stored in an aqueous solution or in a lyophilized state, the preparation of a stabilizing formulation that prevents their deterioration (degradation and aggregation) is crucial. Given the structural similarities of the immunoglobulin G (IgG) framework regions and a diversity of only four subclasses, we aimed to find common conditions that stabilize many different antibodies. In this study, we analyzed the effect of pH (the most critical factor in establishing a stable formulation) on human monoclonal antibodies from subclasses IgG1, IgG2, and IgG4, all of which have been utilized in antibody therapeutics. We found that human IgGs are stable with minimal heat-induced degradation and aggregation at pH 5.0-5.5 irrespective of their subclass. We also found that IgG1 is more susceptible to fragmentation, whereas IgG4 is more susceptible to aggregation. This basic information emphasizing the influence of pH on IgG stability should facilitate the optimization of formulation conditions tailored to individual antibodies for specific uses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686240     DOI: 10.1248/bpb.33.1413

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  33 in total

1.  Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Hannah Joerissen; Beate Müller-Tiemann; Heiner Apeler; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

2.  Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture.

Authors:  James T Heads; Ralph Adams; Lena E D'Hooghe; Matt J T Page; David P Humphreys; Andrew G Popplewell; Alastair D Lawson; Alistair J Henry
Journal:  Protein Sci       Date:  2012-08-09       Impact factor: 6.725

3.  Monoclonal Antibodies Follow Distinct Aggregation Pathways During Production-Relevant Acidic Incubation and Neutralization.

Authors:  Thomas Skamris; Xinsheng Tian; Matthias Thorolfsson; Hanne Sophie Karkov; Hanne B Rasmussen; Annette E Langkilde; Bente Vestergaard
Journal:  Pharm Res       Date:  2015-11-12       Impact factor: 4.200

4.  Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.

Authors:  Shirley J Peters; C Mark Smales; Alistair J Henry; Paul E Stephens; Shauna West; David P Humphreys
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

Review 5.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

6.  Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.

Authors:  Takahiko Ito; Kouhei Tsumoto
Journal:  Protein Sci       Date:  2013-09-30       Impact factor: 6.725

Review 7.  Fragmentation of monoclonal antibodies.

Authors:  Josef Vlasak; Roxana Ionescu
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

8.  Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification.

Authors:  Weixin Jin; Zizhuo Xing; Yuanli Song; Chao Huang; Xuankuo Xu; Sanchayita Ghose; Zheng Jian Li
Journal:  MAbs       Date:  2019-09-02       Impact factor: 5.857

9.  Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.

Authors:  Paolo Arosio; Simonetta Rima; Massimo Morbidelli
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.